Taysha Gene Therapies, Inc. (TSHA) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
8.64
↓-66% vs avg
5yr avg: 25.04
30Y Low1.9·High104.7
ROE
↑
-68.5%
↓+63% vs avg
5yr avg: -186.0%
30Y Low-345%·High-34%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TSHA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Taysha Gene Therapies, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.9B | $1.8B | $433M | $206M | $99M | $439M | $469M | — |
| Enterprise Value | $1.6B | $1.5B | $357M | $123M | $71M | $353M | $218M | — |
| P/E Ratio → | -19.62 | — | — | — | — | — | — | — |
| P/S Ratio | 196.11 | 179.93 | 51.93 | 13.30 | 39.70 | — | — | — |
| P/B Ratio | 8.64 | 7.12 | 6.05 | 2.74 | 104.67 | 4.60 | 1.87 | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TSHA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 149.07 | 42.83 | 7.94 | 28.53 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
TSHA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Taysha Gene Therapies, Inc. earns an operating margin of -1130.6%. Operating margins have compressed from -468.8% to -1130.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -68.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.3% | 88.3% | 100.0% | 100.0% | 0.6% | — | — | — |
| Operating Margin | -1130.6% | -1130.6% | -1097.6% | -468.8% | -5037.1% | — | — | — |
| Net Profit Margin | -1115.3% | -1115.3% | -1071.6% | -722.1% | -6635.3% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -68.5% | -68.5% | -121.9% | -294.0% | -344.7% | -100.7% | -34.2% | — |
| ROA | -43.3% | -43.3% | -53.6% | -74.6% | -97.6% | -73.8% | -33.2% | -7433.3% |
| ROIC | — | — | — | — | — | -2758.7% | — | — |
| ROCE | -49.0% | -49.0% | -67.7% | -72.6% | -111.7% | -83.7% | -34.2% | — |
TSHA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $320M exceeds total debt of $18M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.88 | 0.82 | 63.15 | 0.66 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.22 | -1.06 | -1.11 | -29.45 | -0.90 | -1.00 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | 0.00 |
| Debt / FCF | — | — | — | — | — | — | — | 0.00 |
| Interest Coverage | -1753.94 | -1753.94 | -874.47 | -21.32 | -42.71 | -121.21 | -2142.25 | — |
Net cash position: cash ($320M) exceeds total debt ($18M)
TSHA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Taysha Gene Therapies, Inc.'s current ratio of 12.23x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.08x to 12.23x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.23 | 12.23 | 5.42 | 4.08 | 1.54 | 3.08 | 36.17 | 0.10 |
| Quick Ratio | 12.23 | 12.23 | 5.42 | 4.08 | 1.54 | 3.08 | 36.17 | 0.10 |
| Cash Ratio | 12.04 | 12.04 | 5.30 | 3.92 | 1.40 | 2.88 | 35.24 | — |
| Asset Turnover | — | 0.03 | 0.05 | 0.09 | 0.02 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
TSHA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Taysha Gene Therapies, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $320M | $250M | $116M | $44M | $38M | $18M | $37M |
Peer Comparison
Compare TSHA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TSHAYou | $2B | -19.6 | — | — | 88.3% | -1130.6% | -68.5% | — | — |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 SGMO | $22M | -0.2 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See TSHA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TSHA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TSHA vs SRPT
Side-by-side business, growth, and profitability comparison vs Sarepta Therapeutics, Inc..
Start ComparisonTSHA — Frequently Asked Questions
Quick answers to the most common questions about buying TSHA stock.
What is Taysha Gene Therapies, Inc.'s P/E ratio?
Taysha Gene Therapies, Inc.'s current P/E ratio is -19.6x. This places it at the 50th percentile of its historical range.
What is Taysha Gene Therapies, Inc.'s ROE?
Taysha Gene Therapies, Inc.'s return on equity (ROE) is -68.5%. The historical average is -160.7%.
Is TSHA stock overvalued?
Based on historical data, Taysha Gene Therapies, Inc. is trading at a P/E of -19.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Taysha Gene Therapies, Inc.'s profit margins?
Taysha Gene Therapies, Inc. has 88.3% gross margin and -1130.6% operating margin.